<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2607">
  <stage>Registered</stage>
  <submitdate>8/12/2009</submitdate>
  <approvaldate>8/12/2009</approvaldate>
  <nctid>NCT01029535</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of Juvederm® VOLUMA for Correction of Mid-face Volume Deficiency</studytitle>
    <scientifictitle />
    <utrn />
    <trialacronym />
    <secondaryid>VOL-AP01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Mid-face Volume Deficiency</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Cross-linked hyaluronic acid gel

Experimental: Juvederm® VOLUMA - Juvederm® VOLUMA injected in both sides of face (up to 4 mL per side) at Investigator's discretion to achieve at least a 2-point improvement in the Mid-face Volume Deficit Scale. Participants who completed Week 8 of Phase 1 were eligible to participate in Phase 2 and could receive an additional optional treatment if applicable.


Treatment: devices: Cross-linked hyaluronic acid gel
Cross-linked hyaluronic acid gel (Juvederm® VOLUMA) up to 4 mLs injected in each side of the face.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of Participants With a = 1 Point Improvement From Baseline in the Subject's Global Aesthetic Improvement Scale (GAIS) at Week 4 - The participant rated their midface appearance compared to Baseline (before treatment) using the 5-point GAIS scale where:-2=much worse to +2=much improved. The percentage of participants +1=improved and +2=much improved is reported.</outcome>
      <timepoint>Baseline, Week 4</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants With a = 1 Point Improvement From Baseline in the Subject's Global Aesthetic Improvement Scale (GAIS) at Week 8 - The participant rated their midface appearance compared to Baseline (before treatment) using the 5-point GAIS scale:-2=much worse to +2=much improved. The percentage of participants +1=improved and +2=much improved is reported.</outcome>
      <timepoint>Baseline, Week 8</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants With a = 1 Point Improvement From Baseline in the Physician's Global Aesthetic Improvement Scale (GAIS) at Week 4 - The physician rated the participant's midface appearance compared to Baseline (before treatment) using the 5-point GAIS scale:-2=much worse to +2=much improved. The percentage of participants +1=improved and +2=much improved is reported.</outcome>
      <timepoint>Baseline, Week 4</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants With a = 1 Point Improvement From Baseline in the Physician's Global Aesthetic Improvement Scale (GAIS) at Week 8 - The physician rated the participant's midface appearance compared to Baseline (before treatment) using the 5-point GAIS scale:-2=much worse to +2=much improved. The percentage of participants +1=improved and +2=much improved is reported.</outcome>
      <timepoint>Baseline, Week 8</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants a =1 Point Improvement From Baseline in the Physician's Mid-face Volume Deficit Scale (MFVDS) at Week 4 - The physician determined the degree of midface volume deficiency in each participant, relative to Baseline (before treatment) using the 6-point MFVDS: 0=no facial volume loss to 5=severe volume loss.</outcome>
      <timepoint>Baseline, Week 4</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants a = 1 Point Improvement From Baseline in the Physician's Mid-face Volume Deficit Scale (MFVDS) at Week 8 - The physician determined the degree of midface volume deficiency in each participant, relative to Baseline (before treatment) using the 6-point MFVDS: 0=no facial volume loss to 5=severe volume loss.</outcome>
      <timepoint>Baseline, Week 8</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants Who Maintained Their Week 8 MFVDS Scores at Week 52 - The physician determined the degree of midface volume deficiency in each participant at week 8 and Week 52, relative to before treatment using the 6-point MFVDS: 0-no facial volume loss to 5=severe volume loss. The percentage of participants who are able to maintain their Week 8 score is reported.</outcome>
      <timepoint>Baseline, Week 8, Week 52</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants Who Maintained Their Week 8 MFVDS Scores at Week 78 - The physician determined the degree of midface volume deficiency in each participant at week 8 and Week 78, relative to before treatment using the 6-point MFVDS: 0-no facial volume loss to 5=severe volume loss. The percentage of participants who are able to maintain their Week 8 score is reported.</outcome>
      <timepoint>Baseline, Week 8, Week 78</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants Who Maintained Their Week 8 MFVDS Scores at Week 104 - The physician determined the degree of midface volume deficiency in each participant at week 8 and Week 104, relative to before treatment using the 6-point MFVDS: 0-no facial volume loss to 5=severe volume loss. The percentage of participants who are able to maintain their Week 8 score is reported.</outcome>
      <timepoint>Baseline, Week 8, Week 104</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants Who Maintained Their Week 8 Subject's GAIS Scores at Week 52 - The participant rated their midface appearance compared to before treatment at Week 8 and Week 52 using the 5-point GAIS scale:-2=much worse to +2=much improved. The percentage of participants who are able to maintain their Week 8 score is reported.</outcome>
      <timepoint>Baseline, Week 8, Week 52</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants Who Maintained Their Week 8 Subject's GAIS Scores at Week 78 - The participant rated their midface appearance compared to before treatment at Week 8 and Week 78 using the 5-point GAIS scale:-2=much worse to +2=much improved. The percentage of participants who are able to maintain their Week 8 score is reported.</outcome>
      <timepoint>Baseline, Week 8, Week 78</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants Who Maintained Their Week 8 Subject's GAIS Scores at Week 104 - The participant rated their midface appearance compared to before treatment at Week 8 and Week 104 using the 5-point GAIS scale:-2=much worse to +2=much improved. The percentage of participants who are able to maintain their Week 8 score is reported.</outcome>
      <timepoint>Baseline, Week 8, Week 104</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants Who Maintained Their Week 8 Physician's GAIS Scores at Week 52 - The physician rated the participant's midface appearance compared to before treatment at Week 8 and Week 52 using the 5-point GAIS scale:-2=much worse to +2=much improved. The percentage of participants who are able to maintain their Week 8 score is reported.</outcome>
      <timepoint>Baseline, Week 8, Week 52</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants Who Maintained Their Week 8 Physician's GAIS Scores at Week 78 - The physician rated the participant's midface appearance compared to before treatment at Week 8 and Week 78 using the 5-point GAIS scale:-2=much worse to +2=much improved. The percentage of participants who are able to maintain their Week 8 score is reported.</outcome>
      <timepoint>Baseline, Week 8, Week 78</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants Who Maintained Their Week 8 Physician's GAIS Scores at Week 104 - The physician rated the participant's midface appearance compared to before treatment at Week 8 and Week 104 using the 5-point GAIS scale:-2=much worse to +2=much improved. The percentage of participants who are able to maintain their Week 8 score is reported.</outcome>
      <timepoint>Baseline, Week 8, Week 104</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With a = 1 Point Improvement From Baseline in the Investigator's Wrinkle Assessment Scale (WAS) - The physician assessed the left side and the right side of the participant's face for severity of nasolabial folds using the 5-point WAS where: 0=no wrinkle to 4=very deep wrinkle.</outcome>
      <timepoint>Baseline, Weeks 4, 8, 52, 78 and 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in the MFVDS Score - The physician determined the degree of midface volume deficiency in each participant, relative to Baseline (before treatment) using the 6-point MFVDS where: 0=no facial volume loss to 5=severe volume loss. A negative change from Baseline indicates improvement.</outcome>
      <timepoint>Baseline, Weeks 4, 8, 52, 78 and 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Physician Assessment of Global Aesthetic Improvement Score (GAIS) - The physician rated the participant's midface appearance compared to Baseline (before treatment) using the 5-point GAIS scale:-2=much worse to +2=much improved.</outcome>
      <timepoint>Baseline, Weeks 4, 8, 52, 78 and 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subject's Assessment of Global Aesthetic Improvement Score (GAIS) - The participant rated their midface appearance compared to Baseline (before treatment) using the 5-point GAIS scale:-2=much worse to +2=much improved.</outcome>
      <timepoint>Baseline, Weeks 4, 8, 52, 78 and 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in the Subject's Self-Perception of Age (SPA) - The participant rated their facial age in years at Baseline and Weeks 4, 8, 52, 78 and 104. A negative change from Baseline indicates an improvement.</outcome>
      <timepoint>Baseline, Weeks 4, 8, 52, 78 and 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Satisfied or Very Satisfied With the Treatment - Participants rated their satisfaction with treatment using a 5-Point Scale where: 1=very unsatisfied to 5=very satisfied.</outcome>
      <timepoint>Week 8</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects with mild to severe mid-face and cheek volume deficit due to age-related
             changes, who are likely to improve by at least 2 grades following treatment with the
             study compound, based on a study-specific scale, as assessed by the study physician</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects who have a pre-existing medical condition or who have received any treatments
             or procedures which may impact on the assessment of the effects of the study compound.

          -  Subjects with a history of allergies or other side effects to dermal fillers,
             lidocaine, hyaluronic acid or other component of the study compound.

          -  Subjects were are pregnant or breast-feeding or who are of child-bearing potential and
             who are not prepared to practice an adequate form of contraception during the course
             of the study

          -  Subjects with a history of alcoholism or drug abuse or dependence</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>103</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Sydney</hospital>
    <postcode> - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Allergan</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a prospective, open-label experience study to be conducted at 6 clinical sites in
      Australia, with the objective to collect efficacy and safety information for Juvederm®
      VOLUMA when used for volumising the mid-face and cheek area.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01029535</trialwebsite>
    <publication>Callan P, Goodman GJ, Carlisle I, Liew S, Muzikants P, Scamp T, Halstead MB, Rogers JD. Efficacy and safety of a hyaluronic acid filler in subjects treated for correction of midface volume deficiency: a 24 month study. Clin Cosmet Investig Dermatol. 2013 Mar 20;6:81-9. doi: 10.2147/CCID.S40581. Print 2013.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Director</name>
      <address>Allergan</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>